DGIdb - TEMOZOLOMIDE Drug Record

TEMOZOLOMIDE chembl:CHEMBL810 ApprovedAntineoplasticImmunotherapy

Alternate Names:

SCH-52365
CCRG-81045
M&B-39831
TEMODAL
TEMOZOLOMIDE
M-39831
NSC-362856
TEMODAR
TEMOMEDAC
TEMODAL®
NSC 362856
3-METHYL-4-OXO-3,4-DIHYDROIMIDAZO(5,1-D)(1,2,3,5)TETRAZINE-8-CARBOXAMIDE
3,4-DIHYDRO-3-METHYL-4-OXOIMIDAZO(5,1-D)-AS-TETRAZINE-8-CARBOXAMIDE
MB 39831
CCRG 81045
TÉMOZOLOMIDE
3,4-DIHYDRO-3-METHYL-4-OXOIMIDAZO(5,1-D)-1,2,3,5-TETRAZINE-8-CARBOXAMIDE
TEMOZOLOMID
M & B 39831
TEMODAR®
BRN 5547136
TEMOZOLOMIDUM
TEMOZOLODIDA
TEMOZOLOMIDA
METHAZOLASTONE
M&B 39831
8-CARBAMOYL-3-METHYLIMIDAZO(5,1-D)-1,2,3,5-TETRAZIN-4(3H)-ONE
TMZ
SCH 52365
CCRIS 8996
rxcui:37776
drugbank:00853
pubchem.compound:5394
chembl:CHEMBL810
chemidplus:85622-93-1

Drug Info:

(3 More Sources)

Publications:

Yip et al., 2009, MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance., Clin. Cancer Res.
Cahill et al., 2007, Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment., Clin. Cancer Res.
Peasland et al., 2011, Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines., Br. J. Cancer
Wang X et al., 2014, Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide., Ann Surg Oncol
Trivedi et al., 2005, The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death., Cancer Res.
Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
Watanabe et al., 2011, O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma., Brain Tumor Pathol
Kreth et al., 2011, O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation., PLoS ONE
Chinot et al., 2007, Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide., J. Clin. Oncol.
Rapkins et al., 2015, The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide., Neuro-oncology
Hegi et al., 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma., N. Engl. J. Med.
Barvaux et al., 2004, Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase., Mol. Cancer Ther.
Herrlinger U et al., 2019, Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial., Lancet
Lee et al., 2015, A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients., Clin. Cancer Res.
Eich et al., 2013, Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide., Mol. Cancer Ther.
Valiakhmetova A et al., 2020, Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response., Oncologist
Lewis et al., 2005, A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF., Cancer Invest.
de Gast et al., 2003, Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma., Br. J. Cancer
Bailey et al., 2014, Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition., Mol. Cancer Ther.
Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science
Malmström A et al., 2020, ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide., Pharmacogenomics J
Phillips et al., 2016, ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope., Mol. Cancer Ther.
Kovacs et al., 2007, Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings., Hum. Pathol.
Xu et al., 2016, Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial., Clin. Cancer Res.
Wiestler et al., 2013, ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis., Acta Neuropathol.
Tang SW et al., 2015, SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma., Clin Cancer Res
Lok BH et al., 2017, PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer., Clin Cancer Res

TEMOZOLOMIDE MSH6

Interaction Score: 6.38

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type resistant

Approval Status Preclinical

PMIDs:
19584161 17404084

Sources:
JAX-CKB NCI
TEMOZOLOMIDE SLFN11

Interaction Score: 3.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25779942 27440269

Sources:
CIViC
TEMOZOLOMIDE MGMT

Interaction Score: 1.85

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24444404 21331613 21365007 17442989 25910840 15758010 15486188 30782343

Sources:
NCI CIViC PharmGKB
TEMOZOLOMIDE H2AX

Interaction Score: 1.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16024643

Sources:
NCI
TEMOZOLOMIDE STAG2

Interaction Score: 1.2

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Olaparib + Temozolomide

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
24356817 21852505

Sources:
JAX-CKB
TEMOZOLOMIDE ATRX

Interaction Score: 0.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23904111

Sources:
CIViC
TEMOZOLOMIDE NOTCH1

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Radiotherapy + RO4929097 + Temozolomide

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
27154916

Sources:
JAX-CKB
TEMOZOLOMIDE ATR

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration ATR:.

Drug family Chemotherapy

PMIDs:
None found

Sources:
CGI
TEMOZOLOMIDE BRCA2

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
32043779

Sources:
CIViC
TEMOZOLOMIDE CSF2

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16100942 12610499

Sources:
NCI
TEMOZOLOMIDE PRL

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17056093

Sources:
NCI
TEMOZOLOMIDE ATM

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy

Alteration ATM:.

PMIDs:
23960094

Sources:
CGI CIViC
TEMOZOLOMIDE HDAC4

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24444404

Sources:
PharmGKB
TEMOZOLOMIDE MYC

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy

Alteration MYC:amp

PMIDs:
None found

Sources:
CGI
TEMOZOLOMIDE PTEN

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Vandetanib + Temozolomide

Indication/Tumor Type glioblastoma multiforme

Response Type no benefit

PMIDs:
25910950

Sources:
JAX-CKB
TEMOZOLOMIDE EGFR

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy ABT-414 + Temozolomide + Radiotherapy

Indication/Tumor Type glioblastoma multiforme

Response Type predicted – sensitive

PMIDs:
25910950 26846818

Sources:
JAX-CKB
TEMOZOLOMIDE TP53

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type predicted – sensitive

PMIDs:
21730979 24248532

Sources:
JAX-CKB CIViC
TEMOZOLOMIDE BRCA1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Talazoparib + Temozolomide

Indication/Tumor Type ovarian cancer

Response Type sensitive

PMIDs:
None found

Sources:
JAX-CKB
TEMOZOLOMIDE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31624332

Sources:
PharmGKB
TEMOZOLOMIDE IDH1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase II

Response Type sensitive

PMIDs:
25910950

Sources:
JAX-CKB

NCI: TEMOZOLOMIDE

Version: 14-September-2017

Alternate Names:

C1244 NCI drug code

Drug Info:

Publications:

de Gast et al., 2003, Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma., Br. J. Cancer

Lewis et al., 2005, A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF., Cancer Invest.

Trivedi et al., 2005, The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death., Cancer Res.

PharmGKB: temozolomide

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Malmström A et al., 2020, ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide., Pharmacogenomics J

Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics

JAX-CKB: Temozolomide

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Lee et al., 2015, A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients., Clin. Cancer Res.

Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science

Bailey et al., 2014, Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition., Mol. Cancer Ther.

CIViC: TEMOZOLOMIDE

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Herrlinger U et al., 2019, Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial., Lancet

Rapkins et al., 2015, The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide., Neuro-oncology

Hegi et al., 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma., N. Engl. J. Med.

TTD: Temozolomide
- Version: 2020.06.01
Alternate Names:

D0C8EU TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL810
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
CGI: Temozolomide
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	glioblastoma multiforme
Response Type	resistant
Approval Status	Preclinical

combination therapy	Olaparib + Temozolomide
Indication/Tumor Type	glioblastoma multiforme
Response Type	sensitive

combination therapy	Radiotherapy + RO4929097 + Temozolomide
Indication/Tumor Type	glioblastoma multiforme
Response Type	sensitive

combination therapy	Vandetanib + Temozolomide
Indication/Tumor Type	glioblastoma multiforme
Response Type	no benefit

combination therapy	ABT-414 + Temozolomide + Radiotherapy
Indication/Tumor Type	glioblastoma multiforme
Response Type	predicted – sensitive

Evidence Type	Actionable
Approval Status	Preclinical - Cell culture
Response Type	predicted – sensitive

combination therapy	Talazoparib + Temozolomide
Indication/Tumor Type	ovarian cancer
Response Type	sensitive

Alteration	ATR:.
Drug family	Chemotherapy

Drug family	Chemotherapy
Alteration	ATM:.

Drug family	Chemotherapy
Alteration	MYC:amp

TEMOZOLOMIDE Drug Record

TEMOZOLOMIDE chembl:CHEMBL810 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type glioblastoma multiforme Response Type resistant Approval Status Preclinical

PMIDs: 19584161 17404084

Sources: JAX-CKB NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25779942 27440269

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24444404 21331613 21365007 17442989 25910840 15758010 15486188 30782343

Sources: NCI CIViC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16024643

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Olaparib + Temozolomide Indication/Tumor Type glioblastoma multiforme Response Type sensitive

PMIDs: 24356817 21852505

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23904111

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Radiotherapy + RO4929097 + Temozolomide Indication/Tumor Type glioblastoma multiforme Response Type sensitive

PMIDs: 27154916

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Alteration ATR:. Drug family Chemotherapy

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 32043779

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16100942 12610499

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17056093

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Drug family Chemotherapy Alteration ATM:.

PMIDs: 23960094

Sources: CGI CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24444404

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Drug family Chemotherapy Alteration MYC:amp

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Vandetanib + Temozolomide Indication/Tumor Type glioblastoma multiforme Response Type no benefit

PMIDs: 25910950

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy ABT-414 + Temozolomide + Radiotherapy Indication/Tumor Type glioblastoma multiforme Response Type predicted – sensitive

PMIDs: 25910950 26846818

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell culture Response Type predicted – sensitive

PMIDs: 21730979 24248532

Sources: JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Talazoparib + Temozolomide Indication/Tumor Type ovarian cancer Response Type sensitive

PMIDs: None found

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31624332

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type resistant

Approval Status Preclinical

PMIDs:
19584161 17404084

Sources:
JAX-CKB NCI

Interaction Types & Directionality:

n/a

PMIDs:
25779942 27440269

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
24444404 21331613 21365007 17442989 25910840 15758010 15486188 30782343

Sources:
NCI CIViC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16024643

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Olaparib + Temozolomide

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
24356817 21852505

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
23904111

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Radiotherapy + RO4929097 + Temozolomide

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
27154916

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration ATR:.

Drug family Chemotherapy

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

PMIDs:
32043779

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
16100942 12610499

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17056093

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy

Alteration ATM:.

PMIDs:
23960094

Sources:
CGI CIViC

Interaction Types & Directionality:

n/a

PMIDs:
24444404

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy

Alteration MYC:amp

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Vandetanib + Temozolomide

Indication/Tumor Type glioblastoma multiforme

Response Type no benefit

PMIDs:
25910950

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy ABT-414 + Temozolomide + Radiotherapy

Indication/Tumor Type glioblastoma multiforme

Response Type predicted – sensitive

PMIDs:
25910950 26846818

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type predicted – sensitive

PMIDs:
21730979 24248532

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Talazoparib + Temozolomide

Indication/Tumor Type ovarian cancer

Response Type sensitive

PMIDs:
None found

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
31624332

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase II

Response Type sensitive

PMIDs:
25910950

Sources:
JAX-CKB

Alternate Names:

C1244 NCI drug code

Alternate Names:

D0C8EU TTD Drug ID